The June, 1999 introduction of progestin-only emergency contraceptive (EC) pills on the market on an over-the-counter (OTC) basis in France has spurred an international debate on the deregulation of hormonal emergency contraception. In an effort to provide guidance for public health endeavors to achieve OTC status in other countries, we set out to describe the experience of women who obtained and took EC on a non-prescription basis in France. In particular, we were interested in characterizing the perceived strengths and weaknesses of OTC delivery of EC. To accomplish this, we carried out a series of focus group discussions in France with women who had obtained EC without a prescription in a pharmacy. Each focus group consisted of two parts: a written questionnaire and a guided discussion. We sought to trace the consumer’s entire experience from her decision to seek EC through her experience of obtaining and using the product as well as the final outcome. We were also interested in gathering feedback from the consumers on the nature of any interactions they had with providing pharmacists. Results are pending study completion and data analysis. See www.norlevo.com
Learning Objectives: N/A
Keywords: Contraception, Access and Services
Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: HRA Pharma - market authorization holder for levonorgestrel-only emergency contraception product (NORLEVO)
I have a significant financial interest/arrangement or affiliation with any organization/institution whose products or services are being discussed in this session.
Relationship: Employment